Table 1 Descriptive statistics of the study population at baseline

From: Metabolome in progression to Alzheimer's disease

 

Control

Stable MCI

Progressive MCI

AD

N=226

46

91

52

37

Gender, male/female (%)

21/25 (46/54)

32/59 (35/65)

15/37 (29/71)

17/20 (46/54)

Age at baseline, years (±s.d.)

71±6

72±5

71±6

75±4a

Education, years (±s.d.)

7±2

7±2

7±3

7±3

MMSE (±s.d.)

25.8±2.2

24.6±3.0b

23.7±2.7c

20.5±2.9d

Follow-up time, months (±s.d.)

31±17

28±16

27±18

 

APOE ɛ2/ɛ3/ɛ4, %

0/87/13

4/74/22

3/59/38e

0/65/35f

  1. Abbreviations: AD, Alzheimer’s disease; CI, confidence intervals; MCI, mild cognitive impairment.
  2. aP<0.01 against control, stable MCI and progressive MCI.
  3. bP=0.03 against control.
  4. cP<0.001 against control and P=0.03 against stable MCI.
  5. dP<0.001 against control, stable MCI and progressive MCI.
  6. eχ2-tests P<0.001 for ɛ4 allele against control with odds ratio 4.0 (CI 2.0–8.3) and P<0.01 against stable MCI with odds ratio 2.2 (CI 1.3–3.7).
  7. fχ2-tests P=0.001 for ɛ4 allele against control with odds ratio 3.5 (CI 1.6–7.6) and P=0.02 against stable MCI with odds ratio 1.9 (CI 1.1–3.5).
Back to article page